Home  |  Contact

UniProtKB/Swiss-Prot P50613: Variant p.Gly163Ala

Cyclin-dependent kinase 7
Gene: CDK7
Variant information

Variant position:  163
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Alanine (A) at position 163 (G163A, p.Gly163Ala).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to small size and hydrophobic (A)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page



Sequence information

Variant position:  163
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  346
The length of the canonical sequence.

Location on the sequence:   LLLDENGVLKLADFGLAKSF  G SPNRAYTHQVVTRWYRAPEL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRAPEL

Mouse                         LLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRAPEL

Xenopus laevis                LLLDENGVLKLADFGLAKSFGSPNRIYTHQVVTRWYRSPEL

Caenorhabditis elegans        LLMNKMGRVKLTDFGLARFFGSPNRNYTHQVVTRWYRAPEL

Slime mold                    LLMSINGDLKLADFGLARQYGSPNKVFSPQAVTIFYRAPEL

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 346 Cyclin-dependent kinase 7
Domain 12 – 295 Protein kinase
Modified residue 164 – 164 Phosphoserine; by CDK1 and CDK2
Modified residue 170 – 170 Phosphothreonine; by CDK2
Mutagenesis 164 – 164 S -> A. No mitotic repression of transcriptional activity of the reconstituted TFIIH complex.
Mutagenesis 170 – 170 T -> A. Total loss of activity. Total loss of transcriptional activity of the reconstituted TFIIH complex.


Literature citations

Submission
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS ALA-163 AND MET-285;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.